FrancophonIA/ELRC3.0 huggingface dataset:
English: For adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Estonian: Täiskasvanutel on tavaline soovitatav annus 25 mg kaks korda nädalas või 50 mg üks kord nädalas.
English: Enbrel etanercept
Estonian: Enbrel etanertsept
English: The CHMP decided that Enbrel's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Enbreli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The patient or carer can give the injection if they have been trained appropriately.
Estonian: Patsient või hooldaja võib ravimit ka ise süstida, kui teda on piisavalt juhendatud.
English: The most common side effects with Enbrel (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Estonian: Enbreli kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on süstekoha reaktsioonid (sh verejooks, verevalumid, punetus, sügelus, valu ja turse) ja nakkused (sh nohu ning kopsu-, põieja nahanakkused).
English: In the study of patients who had not taken methotrexate before, those receiving 25 mg Enbrel twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months.
Estonian: Uuringus patsientidega, kes ei olnud varem metotreksaati kasutanud, oli 25 mg Enbrelit kaks korda nädalas saanud patsientidel pärast 12- ja 24-kuulist ravi vähem liigesekahjustusi kui neil, kes kasutasid ainult metotreksaati.
English: Why has Enbrel been approved?
Estonian: Miks Enbrel heaks kiideti?
English: Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine.
Estonian: Enbrelit saavatele patsientidele tuleb anda spetsiaalne hoiatuskaart, millel on ravimi kokkuvõtlik ohutusteave.
English: For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo after three to four months.
Estonian: Kõigi muude uuritud haiguste korral olid sümptomid paranenud 3-4 kuu järel Enbreliga rohkem kui platseeboga.
English: The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients.
Estonian: Viiendas uuringus võrreldi Enbreli, metotreksaadi ja nende kombinatsiooni kasutamise efektiivsust 686 patsiendil.
English: The studies in children with polyarticular juvenile idiopathic arthritis and plaque psoriasis were followed up with long term studies to assess the safety of long term treatment in children.
Estonian: Lapseea idiopaatilise polüartriidi ja hariliku psoriaasiga lastel läbiviidud uuringuid täiendati pikaajaliste uuringutega, et hinnata laste pikaajalise ravi ohutust.
English: What is the risk associated with Enbrel?
Estonian: Mis riskid Enbreliga kaasnevad?
English: In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone.
Estonian: Viiendas uuringus oli Enbrel ainsa ravimina või koos metotreksaadiga efektiivsem kui ainult metotreksaat.
English: What is Enbrel?
Estonian: Mis on Enbrel?
English: By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Estonian: Etanertsept vähendab TNF-i blokeerimisega põletikku ja haiguste muid sümptomeid.
English: Enbrel must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections.
Estonian: Enbrelit ei tohi kasutada patsiendid, kellel on sepsis (bakterite ja toksiinide verre levimine, mis kahjustab elundeid) või selle tekke oht, samuti nakkusega patsiendid.
English: In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before.
Estonian: Neljandas uuringus võrreldi Enbreli ja metotreksaadi kasutamist 632 patsiendil, kes ei olnud varem metotreksaati saanud.
English: For more information about treatment with Enbrel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Enbreliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Enbrel.
Estonian: See on ravimi Enbrel Euroopa avaliku hindamisaruande kokkuvõte.
English: • psoriatic arthritis in adults who have not responded adequately to other treatments;
Estonian: • psoriaatiline artriit täiskasvanutel, kellel ei ole muu raviga tekkinud piisavat ravivastust;
English: The long term safety studies found that Enbrel could be used in polyarticular juvenile idiopathic arthritis in children from the age of two years and plaque psoriasis from the age of six years.
Estonian: Pikaajalise ohutuse uuringutes leiti, et Enbrelit tohib kasutada lapseea idiopaatilise polüartriidi ravis vähemalt 2-aastastel lastel ja hariliku psoriaasi ravis vähemalt 6-aastastel lastel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enbrel.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Enbrel can also be used in patients with severe rheumatoid arthritis who have not taken methotrexate before;
Estonian: Enbrelit tohib kasutada ka raske reumatoidartriidiga patsientidel, kes ei ole varem metotreksaati saanud;
English: Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken arthritis medicines in the past.
Estonian: Kolmes uuringus võrreldi Enbrelit platseeboga (näiva ravimiga) patsientidel, kes olid varem artriidiravimeid kasutanud.
English: Overall, in the studies of rheumatoid arthritis, about two-thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months.
Estonian: Reumatoidartriidi uuringutes olid ligikaudu kahel kolmandikul Enbrelit kasutanud patsientidest 3 kuu pärast sümptomid vähenenud vähemalt 20% võrra.
English: The company that makes Enbrel will provide educational material for doctors expected to prescribe the product (to teach patients how to use the pre-filled pen correctly) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor).
Estonian: Arstide teabematerjal kirjeldab toodet (et nad õpetaksid patsiente pensüstalt õigesti kasutama) ja patsientide teabematerjal kirjeldab raskeid kõrvalnähte, et patsiendid need ära tunneksid ning teaksid, millal on vaja otsekohe arsti poole pöörduda.
English: Enbrel was also compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, 1,263 adults and 211 children with plaque psoriasis, as well as in 225 patients with non-radiographic axial spondyloarthritis.
Estonian: Samuti võrreldi Enbrelit platseeboga lapseea idiopaatilise polüartriidi ravis 51 lapsel, psoriaatilise artriidi ravis 205 täiskasvanul, jäigastava spondüliidi ravis 357 täiskasvanul, hariliku psoriaasi ravis
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Enbrel, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Enbreli ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Etanercept is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA) that makes them able to produce etanercept.
Estonian: Etanertsepti valmistatakse rekombinant-DNA-tehnika abil: seda toodavad rakud, millele on lisatud etanertsepti teket võimaldav geen (DNA).
English: • Severe non-radiographic axial spondyloarthritis (a chronic inflammatory disease of the spine) when there are objective signs of inflammation but no abnormalities seen on x-ray.
Estonian: • raske radioloogilise tõenduseta spondüloartriit (lülisamba krooniline põletikuline haigus), kui esinevad objektiivsed põletikunähud, kuid röntgenuuring ei näita kõrvalekaldeid.
English: Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease.
Estonian: Enbrelit kasutatakse patsientidel, kellel ei ole selle haiguse muule ravile tekkinud ravivastust või kellel ei saa muud ravi kasutada;
English: Enbrel has been studied in five main studies in rheumatoid arthritis, involving about 2,200 patients and lasting from three months to two years.
Estonian: Enbrelit uuriti ligikaudu 2200 patsiendil viies reumatoidartriidi põhiuuringus, mille kestus oli 3 kuud kuni 2 aastat.
English: Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis.
Estonian: Hariliku psoriaasi korral tohib kasutada ka 50 mg kaks korda nädalas 12 esimese ravinädala jooksul.
English: Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient.
Estonian: Enbrelit kasutatakse koos metotreksaadiga (immuunsüsteemi mõjutav ravim) mõõduka või raske haigusega täiskasvanutel, kellel ei ole muu raviga tekkinud piisavat ravivastust, või ainsa ravimina, kui patsient ei saa kasutada metotreksaati.
English: The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF).
Estonian: Enbreli toimeaine etanertsept on valk, mis blokeerib organismis sisalduva virgatsaine - kasvaja nekroositeguri (TNF) - toime.
English: • certain forms of juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in the following groups:
Estonian: • lapseea idiopaatilise artriidi (haruldane lapseea haigus, mille korral põletik on mitmes liigeses) teatud vormid järgmistel patsiendirühmadel:
English: Enbrel is a medicine that contains the active substance etanercept.
Estonian: Enbrel on ravim, mis sisaldab toimeainena etanertsepti.
English: For the full list of all side effects reported with Enbrel, see the package leaflet.
Estonian: Enbreli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Enbrel used?
Estonian: Kuidas Enbrelit kasutatakse?
English: It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection.
Estonian: Seda turustatakse viaalidena, mis sisaldavad süstelahuse pulbrit, ning süstelahust sisaldavate eeltäidetud süstalde ja pensüstaldena.
English: patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate;
Estonian: 2-17-aastased patsiendid, kellel on polüartriit (positiivne või negatiivne reumatoidfaktor) ja veniva kuluga oligoartriit ning kellel ei ole tekkinud metotreksaadile piisavat ravivastust või kes ei talu metotreksaati;
English: Enbrel is an anti inflammatory medicine.
Estonian: Enbrel on põletikuvastane ravim.
English: What is Enbrel used for?
Estonian: Milleks Enbrelit kasutatakse?
English: Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat.
Estonian: Ravi Enbreliga tohib alustada üksnes eriarst, kes on kogenud nende haiguste diagnoosimises ja ravis, mille vastu Enbrelit kasutatakse, ning ravi peab toimuma tema järelevalve all.
English: • plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in patients from the age of six years with long-term severe disease;.
Estonian: • harilik psoriaas (punaseid ketendavaid nahalaike põhjustav haigus) täiskasvanutel mõõdukas kuni raskes vormis ja vähemalt 6-aastastel lastel kroonilises (pikaajalises) vormis.
English: How has Enbrel been studied?
Estonian: Kuidas Enbrelit uuriti?
English: • severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments;
Estonian: • raske jäigastav spondüliit (lülisamba liigeste põletikku põhjustav haigus) täiskasvanutel, kellel ei ole muu raviga tekkinud piisavat ravivastust;
English: What benefit has Enbrel shown during the studies?
Estonian: Milles seisneb uuringute põhjal Enbreli kasulikkus?
English: One of these studies examined Enbrel's effects as an add-on to methotrexate in 89 patients.
Estonian: Neist uuringuist ühes (89 patsienti) uuriti Enbreli toimet kasutamisel lisaks metotreksaadile.
English: How does Enbrel work?
Estonian: Kuidas Enbrel toimib?
English: • moderate to severe rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults (aged 18 years or over).
Estonian: • täiskasvanute (vähemalt 18-aastased) mõõdukas kuni raske reumatoidartriit (liigesepõletikku põhjustav immuunsüsteemi haigus).
English: adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate; adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment.
Estonian: 12-17-aastased noorukid, kellel on psoriaatiline artriit (punaseid ketendavaid nahalaike ja liigesepõletikku põhjustav haigus) ning kellel ei ole tekkinud metotreksaadile piisavat ravivastust või kes ei talu metotreksaati;
English: Patients developing a serious infection should stop Enbrel treatment.
Estonian: Raske nakkuse korral tuleb ravi Enbreliga katkestada.
English: This messenger is found at high levels in patients with the diseases that Enbrel is used to treat.
Estonian: Enbreliga ravitavate haigustega patsientidel on selle virgatsaine sisaldus suur.
English: Chiesi España, S.A. Plaça d'Europa, 41-43, Planta 10, 08908 L'Hospitalet de Llobregat, Barcelona, España
Estonian: Chiesi España, S.A. Plaça d'Europa, 4143, Planta 10, 08908 L'Hospitalet de Llobregat,
English: 11 avenue Dubonnet COURBEVOIE
Estonian: Prantsusmaa CHIESI S.A. 11 avenue Dubonnet COURBEVOIE
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the member states
Estonian: LISA I RAVIMI(TE) NIMETUSTE, RAVIMVORMI(DE), TUGEVUS(T)E, MANUSTAMISVIISI(DE), TAOTLEJA(TE), MÜÜGILOA HOIDJA(TE) LOETELU LIIKMESRIIKIDES
English: Belgium Chiesi Farmaceutici S.p.A. via Palermo 26/A , Parma 43122
Estonian: via Palermo 26/A , Parma 43122
English: Chiesi Limited, Cheadle Royal Business Park, Highfield, Cheadle, Cheshire SK8 3GY, UK
Estonian: Cheadle, Cheshire SK8 3GY,
English: CHIESI S.A.
Estonian: Luksemburg Chiesi Farmaceutici S.p.A.
English: (Mortality was classified as death or euthanasia due to heart failure).
Estonian: (Suremust klassifitseeriti kui südamepuudulikkusest tingitud surma või eutanaasiat.)
English: Date of first authorisation: 20 June 2007 Date of last renewal: 22 May 2012
Estonian: Esmase müügiloa väljastamise kuupäev: 20 juuni 2007 Müügiloa uuendamise kuupäev: 22. mai 2012
English: Pharmacotherapeutic group: Aldosterone antagonist.
Estonian: Farmakoterapeutiline rühm: aldosterooni antagonist.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti (EMA) koduleheküljelt aadressil http://www.ema.europa.eu/.
English: ATCvet code: QC03DA01.
Estonian: ATCvet kood: QC03DA01
English: 5 to 10 kg 10 to 15 kg 15 to 20 kg 20 to 30 kg 30 to 40 kg 40 to 50 kg 50 to 60 kg
Estonian: 5…10 kg 10…15 kg 15…20 kg 20…30 kg 30…40 kg 40…50 kg 50…60 kg
English: Tel: + 33 (0) 5 57 55 40 40 Fax : + 33 (0) 5 57 55 41 98
Estonian: Tel: +33 055 755 4040 Faks: +33 055 755 4198
English: The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding.
Estonian: Tabletti võib segada väikese koguse toiduga, mida pakutakse enne põhisöögikorda või manustada söötmisjärgselt otse suhu.
English: The veterinary medicinal product should be administered with food.
Estonian: Veterinaarravimit tuleb manustada koos toiduga.
English: This is thought to be due to activation of feedback mechanisms without adverse clinical consequence.
Estonian: See võib olla seotud tagasisidemehhanismi aktiveerumisega ilma kliiniliste tagajärgedeta.
English: Ceva Santé Animale 10, av. de La Ballastière 33500 Libourne France
Estonian: Ceva Santé Animale 10 avenue de La Ballastière 33500 Libourne Prantsusmaa
English: Très le Bois 22600 Loudéac France
Estonian: Très le Bois 22600 Loudéac Prantsumaa
English: 30 tablets 180 tablets
Estonian: 30 tabletti 180 tabletti
English: As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and spironolactone.
Estonian: Kuna digoksiini terapeutiline indeks on väga kitsas, on soovitatav jälgida hoolikalt nii digoksiini kui ka spironolaktooni saavaid koeri.
English: The result is an improvement in heart function.
Estonian: Kõige selle tulemusel paraneb südame funktsioon.
English: It is therefore recommended to induce vomiting, gastric lavage (depending on risk assessment) and monitor electrolytes.
Estonian: Seega on soovitatav kutsuda loomal esile oksendamist, teha maoloputus (sõltuvalt tehtud riskianalüüsist) ja jälgida elektrolüüte.
English: Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.
Estonian: Mitte kasutada koertel, kellel esineb hüpoadrenokortitsismi, hüperkaleemiat või hüponatraeemiat.
English: Disposal: read package leaflet.
Estonian: Hävitamine: loe pakendi infolehte.
English: Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration.
Estonian: Spironolaktoon vähendab digoksiini eliminatsiooni ja seega suurendab digoksiini plasmakontsentratsiooni.
English: Do not use during pregnancy and lactation, laboratory studies in species (rat, mouse, rabbit and monkey) have shown evidence of developmental toxicity.
Estonian: Mitte kasutada tiinuse ja laktatsiooni ajal, sest uuringud laboriloomadega (rotid, hiired, jänesed ja ahvid) on näidanud lootetoksilist toimet.
English: Steady-state conditions are reached by day 2.
Estonian: Tasakaalukontsentratsioon saabub 2. päeval.
English: Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could therefore affect the metabolism of other drugs utilizing these metabolic pathways.
Estonian: Spironolaktoon võib põhjustada nii tsütokroom P 450 ensüümide induktsiooni kui ka inhibeerimist ja võib seetõttu häirida teiste samu metaboolseid radasid kasutavate ravimite metabolismi.
English: Ceva Santé Animale ensures that the system of pharmacovigilance, as described in Part I of the marketing authorisation application, is in place and functioning before and whilst the veterinary medicinal product is on the market.
Estonian: Ceva Santé Animale tagab, et enne veterinaarravimi turustamise alustamist ja turustamise ajal on olemas toimiv ravimiohutussüsteem, nagu on kirjeldatud müügiloa taotluse I osas.
English: May cause skin sensitisation: people with known hypersensitivity to spironolactone should avoid contact with the veterinary medicinal product.
Estonian: Võib põhjustada naha ülitundlikkust: inimesed, kellel on teadaolev ülitundlikkus spironolaktooni suhtes, peavad vältima kokkupuudet selle veterinaarravimiga.
English: Plasma clearance of canrenone is 1.45±0.39 l/h/kg and 7α-thiomethyl-spironolactone is 0.89±0.44 l/h/kg.
Estonian: Kanrenooni plasmakliirens on 1,45±0,39 l/h/kg ja 7α-tiometüül-spironolaktoonil 0,89±0,44 l/h/kg.
English: In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.
Estonian: Eksperimetaalsetes mudelites koertega näidati, et pikaajaline ravi aldosterooni antagonistidega hoiab ära vasaku vatsakese düsfunktsiooni progresseerumise ja nõrgendab kroonilise südamepuudulikkusega koertel vasaku vatsakese remodelleerimist.
English: Spironolactone is a natriuretic drug (historically described as a soft diuretic).
Estonian: Spironolaktoon on natriureetiline aine (ajalooliselt kirjeldatud kui “pehme” diureetikum).
English: Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction.
Estonian: Kuigi täpset toimemehhanismi ei ole veel selgitatud, soodustab aldosteroon müokardi fibroosi, müokardiaalset ja vaskulaarset remodelleerimist ja vähendab endoteeli düsfunktsiooni.
English: Do not use in animals used for, or intended for use in breeding.
Estonian: Mitte kasutada loomadel, kes on mõeldud kasutamiseks suguloomadena.
English: In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone.
Estonian: Elulemuse kliinilises uuringus südame paispuudulikkusega koertel saadi 15 kuu pärast spironolaktooniga kombinatsioonis standardraviga ravitud koertel suremuse suhtelise riski 65% langus võrreldes ainult standardravi saanud koertega.
English: Cardboard box containing 3 or 18 blisters of 10 tablets.
Estonian: Pappkarp, mis sisaldab 3 või 18 kümne tabletilist blistrit.
English: EXP: {month/year} Use within 2 months after first opening the bottle.
Estonian: EXP {kuu/aasta} Pärast pudeli esmast avamist kasutada 2 kuu jooksul.
English: Dogs treated concomitantly with spironolactone and NSAIDs should be correctly hydrated.
Estonian: Koertele, keda ravitakse samaaegselt spironolaktooni ja NSAID'dega, tuleb tagada piisav hüdreeritus.
English: The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively.
Estonian: 7α-tiometüül-spironolaktooni ja kanrenooni keskmised jaotusruumalad (Vss) on vastavalt ligikaudu 153 liitrit ja 177 liitrit.
English: After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels from 32 % to 49 % of the administered dose.
Estonian: Pärast spironolaktooni suukaudset manustamist koertele näidati, et kolm metaboliiti saavutasid veres taseme vahemikus 32…49% manustatud annusest.
English: Polyamide/aluminium/polyvinyl chloride//aluminium blisters containing 10 tablets.
Estonian: Polüamiid/alumiinium/polüvinüülkloriid/alumiiniumblistrid, milles on 10 tabletti.
English: Use within 2 months after first opening the bottle.
Estonian: Pärast pudeli esmast avamist kasutada ära 2 kuu jooksul.
English: Symptomatic treatment, e.g., fluid therapy, should be provided.
Estonian: Rakendada võiks ka sümptomaatilist ravi, nt vedelikuteraapiat.
English: EXP: {month/year} Partially used tablets to be used within 7 days.
Estonian: EXP {kuu/aasta} Osaliselt kasutatud tabletid tuleb ära kasutada 7 päeva vältel.
English: In the cardiovascular system, spironolactone prevents the detrimental effects of aldosterone.
Estonian: Kardiovaskuaarsüsteemis hoiab spironolaktoon ära aldosterooni kahjustavad toimed.
English: Partially used tablets should be stored in the original blister and used within 7 days.
Estonian: Osaliselt kasutatud tablette tuleb hoida originaalblisterpakendis ja need tuleb ära kasutada 7 päeva vältel.